Lanean...
Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib
AIM: To evaluate the value of systemic inflammation-based markers as prognostic factors for advanced pancreatic cancer (PC). METHODS: Data from 82 patients who underwent combination chemotherapy with gemcitabine and erlotinib for PC from 2011 to 2014 were collected retrospectively. Data that include...
Gorde:
| Argitaratua izan da: | World J Gastrointest Oncol |
|---|---|
| Egile Nagusiak: | , , , , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Baishideng Publishing Group Inc
2016
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4942744/ https://ncbi.nlm.nih.gov/pubmed/27559435 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4251/wjgo.v8.i7.555 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|